LinkGevity appears at Milken Institute Global Conference

LinkGevity CEO Dr. Carina Kern joined other global leaders across biotech, medicine, AI, and consumer health at Milken Institute Global Conference to discuss the next phase of longevity science and healthy aging.

The discussion included: Joe Betts-LaCroix, Founder & CEO of Retro Biosciences;  John Whyte, CEO of the American Medical Association; Tom Hale, CEO of Oura Health;  Richard Isaacson of Atria Health and Research Institute and  Richard Lui, Founder of CAREGenome

Carina shared progress on LinkGevity's first-in-class Anti-Necrotic™ therapeutic platform, targeting a fundamental driver of biological degeneration and ageing as we move toward clinical trials.

One theme stood out clearly across the discussion: longevity science is entering a translational era. The convergence of AI, precision medicine, and next-generation therapeutics is accelerating the shift from scientific discovery to clinically actionable interventions.

The full discussion can be found here: https://youtu.be/vg2PvTIqCbs?si=wNjj2fLm7n34nVh3